Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
← Haematology and transfusion indexChapter sections
OverviewAetiologyPathophysiologyClinical features and red flagsInvestigationsDifferential diagnosisManagementComplicationsMonitoring and follow-upSpecial situationsCommon pitfallsQuestionsSources
Full textbook13 sectionsOpen only what you need
Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.

Monoclonal gammopathy of undetermined significance

Haematology and transfusion · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull
!
Paraprotein with acute organ injury

New renal failure, hypercalcaemia, cord symptoms, hyperviscosity, severe neuropathy, haemolysis, nephrotic syndrome or heart failure is not uncomplicated MGUS and requires urgent reclassification.

Action: Assess ABCDE, obtain FBC, calcium, renal, liver, SPEP, immunofixation, free light chains, urine and organ-specific tests, treat the acute syndrome and refer urgently to haematology, renal, neurology or cardiology for marrow, tissue and imaging rather than waiting for routine MGUS review.

Overview

Confirm MGUS without missing myeloma, lymphoma, amyloid or monoclonal gammopathy of clinical significance, stratify progression risk and provide proportionate monitoring with clear re-referral triggers.

MGUS is common with ageing and is usually discovered during evaluation of neuropathy, anaemia, renal impairment, inflammation or high total protein. Before accepting the label, ask about bone pain, fracture, infection, weight loss, sweats, neuropathy, bleeding, headache, visual change, oedema, dyspnoea and autonomic symptoms. Examine nodes, spleen, skeletal tenderness, neuropathy, heart failure, macroglossia and purpura. The central question is not merely whether a monoclonal band exists, but whether the clone or its protein is already causing disease.

Characterise the clone with SPEP, immunofixation, quantitative immunoglobulins and serum free light chains. Check FBC, creatinine or eGFR, calcium, albumin and liver tests and use urinalysis and protein or albumin quantification. Interpret free-light-chain ratio with kidney function and the renal reference context; a polyclonal rise in both chains differs from a dominant involved chain. Review previous results to distinguish a long stable band from rapid emergence. A very small band can still produce AL amyloid or renal disease.

Practice

Two practice questions

Your practice draft is saved in this browser.

Question 1 of 2
0 correct
Haematology and transfusionOriginal SBA

Low-risk MGUS pattern

An asymptomatic adult has an IgG monoclonal protein 8 g/L, normal free-light-chain ratio, normal haemoglobin, calcium and renal function and no bone or amyloid symptoms. Which approach is most appropriate?

Choose one answer, then submit
← Rapid synopsisBack to overviewAll Haematology and transfusion topics →
Sources and review status3 sources · checked 27 Aug 2026 · clinical review pending+
Sources

Sources and review status

National guidance is shown before implementation-dependent detail. Apply principles in context and verify current guidance when a decision affects care. Source check completed 27 Aug 2026; clinical approval remains outstanding.

  • British Society for Haematology MGUS good practice paperCurrent UK diagnosis, risk, monitoring and MGCS guidance.
  • NICE NG35 myeloma recommendationsUK paraprotein testing, imaging and active-myeloma exclusion.
  • British Society for Haematology early AL amyloidosis guidelineCurrent 2026 red flags for a small amyloidogenic clone.

Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

Authoring stateComplete draftClinical stateAwaiting reviewJurisdictionUnited Kingdom
Non-IgM MGUS has M-protein below 30 g/L, marrow clonal plasma cells below 10% and no myeloma-defining event. IgM MGUS has IgM below 30 g/L, lymphoplasmacytic marrow involvement below 10% and no related symptoms such as anaemia, hyperviscosity, nodes or spleen. Light-chain MGUS requires abnormal ratio with increased involved chain, no heavy-chain immunofixation, clonal marrow below 10%, urinary monoclonal protein below 500 mg/24 hours and no attributable organ injury. If marrow is not clinically required in a low-risk phenotype, diagnosis uses the complete non-invasive context.

Escalate investigation when M-protein is larger or non-IgG, ratio markedly abnormal, unexplained anaemia or renal impairment exists, calcium is high, symptoms are present or results progress. Marrow aspirate and trephine with flow and FISH distinguish plasma-cell and lymphoplasmacytic clones. Whole-body MRI or low-dose CT assesses myeloma bone disease; CT assesses nodes and spleen in IgM disease. Tissue biopsy is essential for suspected amyloid, monoclonal renal lesion or neuropathic process. Do not attribute common CKD or anaemia to the clone without mechanism.

A simple risk model uses three factors: non-IgG isotype, M-protein at least 15 g/L and abnormal free-light-chain ratio. Absence of all identifies a low-risk group, while accumulating factors raises long-term progression probability. This model supports but does not replace isotype-specific assessment, dynamic change, immunoparesis and patient life expectancy. A rapidly changing lower absolute value can be more concerning than a stable larger value. Explain that average progression is approximately 1% per year but individual risk is not constant or identical.

Monitoring should be proportionate. Recheck the clinical and laboratory picture after initial diagnosis to confirm stability. Low-risk stable MGUS can often move to primary-care monitoring or discharge with BSH safety-netting; intermediate and high-risk or IgM and light-chain phenotypes require a defined interval, commonly at least annual after early stability. At review assess symptoms, FBC, renal function, calcium and the same clonal marker. Do not perform routine serial skeletal surveys or PET. Image new pain and repeat marrow when a biochemical or clinical change can alter classification.

Monoclonal gammopathy of clinical significance is the critical exception. MGRS includes light-chain deposition, proliferative glomerulonephritis and other clone-mediated kidney lesions confirmed by renal biopsy and expert typing. Neuropathy may reflect anti-MAG IgM, cryoglobulin, POEMS or amyloid. Skin, eye and complement disorders also occur. These patients may need clone-directed treatment despite not meeting myeloma or lymphoma tumour criteria, because the treatment target is the pathogenic protein and endangered organ rather than clone size.

Communicate risk without turning a precursor state into active cancer. Provide written symptoms that trigger earlier assessment and identify who owns follow-up. Avoid repeated testing more often than an action could reasonably follow, particularly in frail patients with stable low-risk disease. Address osteoporosis through fracture-risk guidance, vaccination and recurrent infection conventionally. Family screening is not indicated. A new cancer diagnosis or immunosuppressive treatment is an opportunity to review the paraprotein but not an automatic reason to treat it.

Key points

  • MGUS is a diagnosis of exclusion: define the monoclonal isotype and burden, then show absence of a myeloma-defining event, lymphoma and protein-mediated organ disease.
  • Non-IgM MGUS usually has serum M-protein below 30 g/L, clonal marrow plasma cells below 10% and no attributable SLiM-CRAB event.
  • Light-chain MGUS has an abnormal free-light-chain ratio with raised involved light chain, no heavy-chain expression, marrow clonal plasma cells below 10% and urinary monoclonal protein below 500 mg/24 hours.
  • Initial tests are FBC, calcium, renal, liver, SPEP, immunofixation, quantitative immunoglobulins, free light chains and urinalysis or protein quantification plus symptom and examination review.
  • Do not perform routine marrow or whole-body imaging in every clearly low-risk asymptomatic IgG MGUS case, but investigate unexplained red flags, higher burden, IgM or light-chain disease appropriately.
  • Common progression risk factors are non-IgG isotype, M-protein at least 15 g/L and abnormal free-light-chain ratio; risk category guides follow-up intensity.
  • A stable low-risk patient may be returned to primary care or discharged with explicit blood-test and symptom triggers under the BSH pathway; higher-risk disease needs structured haematology follow-up.
  • MGUS itself is not treated with chemotherapy; treat osteoporosis, infection and cardiovascular risks conventionally and treat a demonstrable monoclonal protein-mediated disorder through its specialist pathway.
  • A small clone does not mean harmless protein: renal biopsy, nerve assessment or Congo-red tissue may reveal monoclonal gammopathy of clinical significance or AL amyloid.
  • Do not screen the general population and do not repeatedly test a paraprotein without explaining the purpose, interval and action threshold.

Aetiology

01

Small clonal precursor

MGUS is a limited plasma-cell or B-cell clone that secretes monoclonal immunoglobulin without tumour burden or organ injury sufficient for malignancy.

02

Age-related clonal selection

Prevalence rises substantially with age and reflects accumulated somatic lesions and marrow microenvironment changes rather than an infectious or lifestyle cause.

03

Host susceptibility

Risk is higher with male sex, Black ancestry and family history, but screening asymptomatic populations is not currently recommended.

Pathophysiology

  1. 1
    Stable clone–host equilibrium

    Most clones remain constrained by immune surveillance and limited genetic drivers, producing a measurable protein without progressive tissue infiltration.

  2. 2
    Progression through additional lesions

    Some non-IgM clones evolve through smouldering to myeloma, while IgM MGUS more often progresses to lymphoplasmacytic lymphoma or another B-cell neoplasm.

  3. 3
    Protein-mediated injury

    Even a small clone can produce nephrotoxic, amyloidogenic, cryoprecipitating, complement-activating or nerve-reactive immunoglobulin and create clinical significance without malignancy criteria.

  4. 4
    Immunoparesis and bone context

    Selected higher-risk clones suppress normal immunoglobulins and associate with infection, fracture and thrombotic risk, requiring attention beyond M-protein size alone.

Clinical features and red flags

Incidental monoclonal band

A discrete SPEP or immunofixation band is often found without symptoms, but isotype and free-light-chain context determine the next step.

Myeloma warning

Bone pain, fracture, anaemia, renal decline, hypercalcaemia or infection requires active myeloma assessment rather than routine MGUS follow-up.

IgM warning

Neuropathy, headache, visual change, bleeding, nodes, spleen or cold symptoms suggest Waldenstrom or an IgM-related disorder.

Amyloid warning

Proteinuria, restrictive cardiac symptoms, orthostatic hypotension, macroglossia or periorbital bruising needs urgent amyloid evaluation.

Dynamic progression

A rising band or involved light chain, new immunoparesis or changing ratio is more important than a single stable measurement.

Red flags requiring action

  • New bone pain, fracture, anaemia, hypercalcaemia, renal decline or recurrent infection raises active myeloma and requires repeat clonal and whole-body assessment.
  • Proteinuria, oedema, restrictive cardiomyopathy, autonomic neuropathy, macroglossia or periorbital bruising suggests AL amyloidosis and needs urgent tissue typing.
  • Headache, visual disturbance, mucosal bleeding or neurological symptoms with an IgM paraprotein suggests hyperviscosity and cannot wait for routine surveillance.
  • A rapidly rising M-protein, markedly changing free-light-chain ratio, constitutional symptoms, nodes or spleen requires lymphoma or plasma-cell re-evaluation.

Investigations

  1. 01
    First-line monoclonal studiesFirst stepFirst line
    Why
    Confirm isotype, concentration and light-chain clonality.
    Interpretation and limitations
    Use SPEP, immunofixation, quantitative immunoglobulins and serum free light chains together; account for renal function and do not call a broad polyclonal rise MGUS.
  2. 02
    Organ-injury screen
    Why
    Exclude active myeloma and identify protein-mediated disease.
    Interpretation and limitations
    Check FBC, renal, calcium, albumin, liver, urinalysis and protein quantification; investigate bone, cardiac, neurological or systemic symptoms rather than relying on normal CRAB tests.
  3. 03
    Selective marrow aspirate and trephine
    Why
    Quantify and phenotype a higher-risk, IgM, light-chain or clinically suspicious clone.
    Interpretation and limitations
    Use morphology and flow, plasma-cell FISH or MYD88-directed testing as appropriate; 10% clonal burden changes the precursor classification.
  4. 04
    Selective whole-body or nodal imaging
    Why
    Exclude lytic disease, plasmacytoma, lymphadenopathy or organomegaly when risk or symptoms warrant.
    Interpretation and limitations
    Use whole-body MRI or low-dose CT for myeloma concern and CT for IgM lymphoma pattern; do not use routine isotope bone scan.
  5. 05
    Organ biopsy with definitive typing
    Why
    Prove monoclonal renal, amyloid or other tissue injury that can justify therapy.
    Interpretation and limitations
    Use renal electron microscopy and immunotyping or Congo red plus mass spectrometry through an expert centre; a circulating clone alone does not prove causality.

Differential diagnosis

01

Polyclonal gammopathy

Inflammation, infection and liver disease create a broad electrophoretic increase rather than a discrete immunofixation-defined monoclonal protein.

02

Smouldering or active myeloma

Greater marrow burden, M-protein and any attributable SLiM-CRAB event moves the diagnosis beyond MGUS and can create a treatment indication.

03

Waldenstrom macroglobulinaemia

IgM secretion with marrow lymphoplasmacytic lymphoma, symptoms or greater infiltration requires marrow, MYD88 and clinical classification rather than an MGUS label.

04

AL amyloid or MGCS

Organ injury caused by monoclonal protein can require clone-directed therapy despite a small marrow clone and absent conventional myeloma features.

Management

01New monoclonal proteinConfirm clone and search for consequenceFirst stepSPEP, immunofixation or free-light-chain testing detects possible monoclonality.+
  1. 1Repeat or complete isotype, concentration, immunoglobulin and free-light-chain characterisation with FBC, renal, calcium, urine and symptom assessment.
  2. 2EscalationEscalate marrow, whole-body imaging, CT or tissue biopsy when burden, isotype, dynamic change or organ features warrant.
  3. 3Classify non-IgM, IgM or light-chain MGUS only after excluding active malignancy, amyloid and monoclonal gammopathy of clinical significance.
02Low-risk MGUSConfirm stability and safety-netIgG M-protein is below 15 g/L, free-light-chain ratio is normal and no red flag exists.+
  1. 1Confirm clinical and laboratory stability at the BSH-recommended early reassessment.
  2. 2Return to proportionate primary-care monitoring or discharge according to local pathway and life expectancy.
  3. 3Provide explicit early re-referral triggers for pain, anaemia, renal, calcium, infection, neuropathy, amyloid and rising protein.
03Higher-risk or changing MGUSInvestigate and follow through haematologyNon-IgG, M-protein at least 15 g/L, abnormal ratio, immunoparesis or biochemical change exists.+
  1. 1Review previous trajectory and perform marrow and subtype-appropriate imaging when the result changes classification.
  2. 2Exclude smouldering or active myeloma, Waldenstrom, lymphoma and organ-specific monoclonal disease.
  3. 3Set a named interval and action thresholds, commonly annual after early stability but sooner for a changing marker.
04Possible MGCSProve protein-mediated organ injuryRenal, neurological, cardiac, skin, eye or other dysfunction is plausibly linked to the monoclonal protein.+
  1. 1AlternativeRefer to the relevant organ and haematology specialists and exclude common alternative causes.
  2. 2DefinitiveObtain definitive tissue or serological mechanism evidence with expert clone and protein typing.
  3. 3Treat the pathogenic clone when organ benefit justifies it, even if conventional tumour thresholds remain below malignancy criteria.

Complications

01

Progression to malignancy

Non-IgM MGUS can progress to myeloma and IgM MGUS to lymphoplasmacytic or other lymphoma, with risk varying by measurable factors.

02

Monoclonal gammopathy of clinical significance

Renal, neurological, dermatological, ocular and other tissue injury can occur through the protein and requires mechanism-specific specialist care.

03

AL amyloidosis

An amyloidogenic light chain may deposit in heart, kidney, nerves, liver or soft tissue despite a small apparently MGUS-sized clone.

04

Infection and skeletal risk

Some patients have immunoparesis, recurrent infection, osteoporosis or fracture risk that should be assessed independently of progression surveillance.

Monitoring and follow-up

  • At each review ask specifically about bone pain, fracture, infection, neuropathy, bleeding, visual symptoms, weight loss, oedema, dyspnoea and postural symptoms.
  • Repeat FBC, renal function, calcium and the same quantitative monoclonal marker so trend is interpretable; avoid switching assays without context.
  • Bring assessment forward for a rising M-protein or involved light chain, changing ratio, new immunoparesis or any attributable organ abnormality.
  • Do not use routine serial PET, skeletal survey or marrow in stable asymptomatic MGUS; select imaging or biopsy for a defined clinical change.
  • Document follow-up owner, interval, stopping considerations in limited life expectancy and explicit urgent re-referral thresholds.

Special situations

Undetermined is not harmless

The tumour burden may be small while an unusual antibody injures kidney, nerve or heart. Clinical significance and malignant progression are separate axes.

Isotype predicts destination

Non-IgM clones usually progress along the plasma-cell pathway, while IgM clones more often evolve into lymphoplasmacytic or other B-cell lymphoma.

Trend needs one ruler

Following the same quantified M-protein and involved light chain is more informative than frequent panels interpreted without baseline or renal context.

Risk is lifelong

Progression risk persists rather than disappearing after several stable years, but surveillance intensity should still reflect absolute risk, age and actionability.

Biopsy establishes causality

A paraprotein is common in older adults. Renal or other organ biopsy prevents treating a coincidental clone for unrelated disease.

Common pitfalls

  1. 01

    Do not call a broad inflammatory gamma rise MGUS without immunofixation-defined monoclonality.

  2. 02

    Do not diagnose harmless MGUS while ignoring proteinuria, cardiomyopathy, neuropathy or hyperviscosity.

  3. 03

    Do not perform indiscriminate population screening or marrow and PET testing in every low-risk asymptomatic case.

  4. 04

    Do not apply the non-IgM plasma-cell pathway to IgM MGUS without assessing lymphoplasmacytic disease.

  5. 05

    Do not treat the paraprotein number with chemotherapy in uncomplicated MGUS.

  6. 06

    Do not discharge a patient without a named follow-up owner and written progression and organ-injury triggers.